biote Corp.(BTMD)Stock Analysis

BTMD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for biote Corp. (BTMD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BTMD at 56.6/100 on a 32-signal composite quality model, placing it at rank #1,089 of 2,879 stocks — the top half of the AI-ranked universe. BTMD scores in the top quartile across balance sheet strength (98.2), profitability (82.5). Areas of concern include institutional flow (17.6) and revenue scale (23.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 27.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), biote Corp. reports quarterly revenue of $44.9M, net income of $2.3M, free cash flow of $3.5M. Top institutional holders of BTMD by reported 13-F value include 325 CAPITAL, Bandera Partners, BlackRock,, based on the most recent SEC filings. BTMD trades on the Nasdaq exchange and files with the SEC under CIK 1819253. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BTMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for biote Corp. directly from SEC EDGAR. biote Corp.'s 13F Pro composite quality score has ranged between 8 and 63 since 2023, currently 56.6 — an improving long-term trajectory across 48 quarterly and live scoring snapshots.